AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.57+0.20 (+0.19%) ▲|ACN180.39+2.49 (+1.40%) ▲|ADBE245.07-3.76 (-1.51%) ▼|AMAT457.40+3.39 (+0.75%) ▲|AMD503.03-0.57 (-0.11%) ▼|AMGN384.30+1.83 (+0.48%) ▲|AMT175.60+2.61 (+1.51%) ▲|AMZN256.21+4.32 (+1.72%) ▲|AVGO363.48+2.65 (+0.73%) ▲|AXP324.91+4.18 (+1.30%) ▲|BA208.54+3.69 (+1.80%) ▲|BAC63.78+1.21 (+1.93%) ▲|BKNG174.28+0.37 (+0.21%) ▲|BLK1,080.99+18.45 (+1.74%) ▲|BMY64.05+0.31 (+0.48%) ▲|BNY164.33+1.72 (+1.05%) ▲|BRK-B509.04+2.03 (+0.40%) ▲|C140.92+2.39 (+1.72%) ▲|CAT817.78+12.78 (+1.59%) ▲|CL88.34+0.45 (+0.51%) ▲|CMCSA25.31+0.14 (+0.54%) ▲|COF210.58+3.49 (+1.69%) ▲|COP135.82-1.23 (-0.90%) ▼|COST905.11+2.73 (+0.30%) ▲|CRM247.90+4.80 (+1.97%) ▲|CSCO109.40+1.96 (+1.82%) ▲|CVS96.04+0.75 (+0.79%) ▲|CVX213.29+0.53 (+0.25%) ▲|DE689.56+11.61 (+1.71%) ▲|DHR202.36+1.88 (+0.94%) ▲|DIS106.49+0.64 (+0.61%) ▲|DUK119.81+0.41 (+0.34%) ▲|EMR150.20+1.82 (+1.23%) ▲|FDX314.52+2.70 (+0.86%) ▲|GD355.64+1.35 (+0.38%) ▲|GE328.12+4.00 (+1.23%) ▲|GEV950.00+26.61 (+2.88%) ▲|GILD145.64+0.83 (+0.57%) ▲|GM87.15+1.05 (+1.22%) ▲|GOOG337.20+6.81 (+2.06%) ▲|GOOGL339.35+6.75 (+2.03%) ▲|GS1,037.83+18.10 (+1.77%) ▲|HD311.00+5.30 (+1.73%) ▲|HON203.43+1.25 (+0.62%) ▲|IBM236.56+2.49 (+1.06%) ▲|INTC101.41+1.09 (+1.08%) ▲|INTU318.36+5.59 (+1.79%) ▲|ISRG372.53+12.07 (+3.35%) ▲|JNJ269.03+2.69 (+1.01%) ▲|JPM359.72+6.23 (+1.76%) ▲|KO88.40+0.57 (+0.65%) ▲|LIN464.16+2.54 (+0.55%) ▲|LLY1,127.01+3.74 (+0.33%) ▲|LMT529.21-0.77 (-0.15%) ▼|LOW199.46+2.86 (+1.46%) ▲|LRCX299.94+1.93 (+0.65%) ▲|MA568.38+2.96 (+0.52%) ▲|MCD253.82+0.79 (+0.31%) ▲|MDLZ62.69+0.22 (+0.35%) ▲|MDT92.25+0.63 (+0.69%) ▲|META659.47+15.09 (+2.34%) ▲|MMM163.29+0.43 (+0.26%) ▲|MO69.49+0.73 (+1.06%) ▲|MRK145.06+0.34 (+0.23%) ▲|MS216.60+3.89 (+1.83%) ▲|MSFT496.81+4.37 (+0.89%) ▲|MU978.18+0.77 (+0.08%) ▲|NEE82.95+0.49 (+0.59%) ▲|NFLX76.94+0.93 (+1.22%) ▲|NKE36.94+0.33 (+0.89%) ▲|NOW133.76+2.58 (+1.97%) ▲|NVDA219.49+1.13 (+0.52%) ▲|ORCL156.50+3.33 (+2.17%) ▲|PEP136.99+0.34 (+0.25%) ▲|PFE27.66+0.02 (+0.07%) ▲|PG144.83+1.83 (+1.28%) ▲|PLTR166.88+1.02 (+0.61%) ▲|PM192.68+2.95 (+1.55%) ▲|QCOM181.56+4.68 (+2.65%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO609.66+6.51 (+1.08%) ▲|TMUS180.03+2.87 (+1.62%) ▲|TSLA364.96+1.40 (+0.38%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.57+0.20 (+0.19%) ▲|ACN180.39+2.49 (+1.40%) ▲|ADBE245.07-3.76 (-1.51%) ▼|AMAT457.40+3.39 (+0.75%) ▲|AMD503.03-0.57 (-0.11%) ▼|AMGN384.30+1.83 (+0.48%) ▲|AMT175.60+2.61 (+1.51%) ▲|AMZN256.21+4.32 (+1.72%) ▲|AVGO363.48+2.65 (+0.73%) ▲|AXP324.91+4.18 (+1.30%) ▲|BA208.54+3.69 (+1.80%) ▲|BAC63.78+1.21 (+1.93%) ▲|BKNG174.28+0.37 (+0.21%) ▲|BLK1,080.99+18.45 (+1.74%) ▲|BMY64.05+0.31 (+0.48%) ▲|BNY164.33+1.72 (+1.05%) ▲|BRK-B509.04+2.03 (+0.40%) ▲|C140.92+2.39 (+1.72%) ▲|CAT817.78+12.78 (+1.59%) ▲|CL88.34+0.45 (+0.51%) ▲|CMCSA25.31+0.14 (+0.54%) ▲|COF210.58+3.49 (+1.69%) ▲|COP135.82-1.23 (-0.90%) ▼|COST905.11+2.73 (+0.30%) ▲|CRM247.90+4.80 (+1.97%) ▲|CSCO109.40+1.96 (+1.82%) ▲|CVS96.04+0.75 (+0.79%) ▲|CVX213.29+0.53 (+0.25%) ▲|DE689.56+11.61 (+1.71%) ▲|DHR202.36+1.88 (+0.94%) ▲|DIS106.49+0.64 (+0.61%) ▲|DUK119.81+0.41 (+0.34%) ▲|EMR150.20+1.82 (+1.23%) ▲|FDX314.52+2.70 (+0.86%) ▲|GD355.64+1.35 (+0.38%) ▲|GE328.12+4.00 (+1.23%) ▲|GEV950.00+26.61 (+2.88%) ▲|GILD145.64+0.83 (+0.57%) ▲|GM87.15+1.05 (+1.22%) ▲|GOOG337.20+6.81 (+2.06%) ▲|GOOGL339.35+6.75 (+2.03%) ▲|GS1,037.83+18.10 (+1.77%) ▲|HD311.00+5.30 (+1.73%) ▲|HON203.43+1.25 (+0.62%) ▲|IBM236.56+2.49 (+1.06%) ▲|INTC101.41+1.09 (+1.08%) ▲|INTU318.36+5.59 (+1.79%) ▲|ISRG372.53+12.07 (+3.35%) ▲|JNJ269.03+2.69 (+1.01%) ▲|JPM359.72+6.23 (+1.76%) ▲|KO88.40+0.57 (+0.65%) ▲|LIN464.16+2.54 (+0.55%) ▲|LLY1,127.01+3.74 (+0.33%) ▲|LMT529.21-0.77 (-0.15%) ▼|LOW199.46+2.86 (+1.46%) ▲|LRCX299.94+1.93 (+0.65%) ▲|MA568.38+2.96 (+0.52%) ▲|MCD253.82+0.79 (+0.31%) ▲|MDLZ62.69+0.22 (+0.35%) ▲|MDT92.25+0.63 (+0.69%) ▲|META659.47+15.09 (+2.34%) ▲|MMM163.29+0.43 (+0.26%) ▲|MO69.49+0.73 (+1.06%) ▲|MRK145.06+0.34 (+0.23%) ▲|MS216.60+3.89 (+1.83%) ▲|MSFT496.81+4.37 (+0.89%) ▲|MU978.18+0.77 (+0.08%) ▲|NEE82.95+0.49 (+0.59%) ▲|NFLX76.94+0.93 (+1.22%) ▲|NKE36.94+0.33 (+0.89%) ▲|NOW133.76+2.58 (+1.97%) ▲|NVDA219.49+1.13 (+0.52%) ▲|ORCL156.50+3.33 (+2.17%) ▲|PEP136.99+0.34 (+0.25%) ▲|PFE27.66+0.02 (+0.07%) ▲|PG144.83+1.83 (+1.28%) ▲|PLTR166.88+1.02 (+0.61%) ▲|PM192.68+2.95 (+1.55%) ▲|QCOM181.56+4.68 (+2.65%) ▲|RTX198.38+0.30 (+0.15%) ▲|SBUX99.78+0.56 (+0.56%) ▲|SCHW106.72-0.61 (-0.57%) ▼|SO88.21+0.46 (+0.52%) ▲|SPG205.01+0.27 (+0.13%) ▲|T25.91+0.35 (+1.35%) ▲|TMO609.66+6.51 (+1.08%) ▲|TMUS180.03+2.87 (+1.62%) ▲|TSLA364.96+1.40 (+0.38%) ▲|TXN267.37+8.55 (+3.30%) ▲|UBER72.19-0.37 (-0.51%) ▼|UNH385.23-3.05 (-0.79%) ▼|UNP287.61+1.83 (+0.64%) ▲|UPS100.00+0.03 (+0.03%) ▲|USB62.88+0.47 (+0.75%) ▲|V368.49+1.28 (+0.35%) ▲|VZ50.40+0.43 (+0.86%) ▲|WFC90.41+0.96 (+1.07%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.55+0.32 (+0.19%) ▲|
21.9 C
New York
Friday, September 11, 2026

Tag: data

newssourceFORcompanyinformationcontent1releasesmarket

Changan Group Unveils Its In-house Developed ADAS — SDA Pilot

CHONGQING, China, June 14, 2026 /PRNewswire/ -- At the 28th Chongqing International Auto Exhibition, Changan Group showcased its full brand lineup including CHANGAN NEVO,...

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex’s leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

$100 No Deposit Bonus 200 Free Spins Real Money Casinos – All iGaming Experts Report Rising Demand for Free Spins Casinos

Vancouver, Canada, June 14, 2026 (GLOBE NEWSWIRE) --

$100 no deposit bonus 200 free spins real money promotions remain widely discussed as players look for practical ways to evaluate free spins casinos before making a deposit. As 50 no deposit free spins for real money bonus continue attracting players, many users are taking a closer look at promotional details and the overall value offered by no deposit bonus casinos.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026

RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) will highlight that the value of artificial intelligence in healthcare is measured not by technological complexity alone, but by its ability to give clinicians more time, patients better experiences, and health systems greater capacity to deliver specialized care.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 4, 2026.

Nalvurikenz Officially Launches Its Advanced AI Trading Platform for the Next Generation of Intelligent Investing in 2026

New York City, June 13, 2026 (GLOBE NEWSWIRE) --

In 2026, Nalvurikenz officially announced the release of its new AI-powered trading platform, integrating unique features and functionalities to simplify the trading process using a combination of artificial intelligence, live data analytics, and advanced automation.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

There Are 16 Minerals America Produces None Of. The Government Now Calls That a National Security Threat.

A former Pentagon advisor on what Washington is doing about it and where he's looking on U.S. soil. 
A former Pentagon advisor on what Washington is doing about it and where he's looking on U.S. soil.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

TTW Announces Top 50 Amusement Park Travel Destinations in the World for 2026

NEW YORK, June 13, 2026 /PRNewswire/ -- Travel And Tour World (TTW) today announced its Top 50 Amusement Park Travel Destinations in the World...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsData

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers